Andere Sprachen Kiniksa Pharmaceuticals, Ltd.

Aktien

A2JMVJ

BMG5269C1010

KNSA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
17.61 ^USD	-1.40%		+4.32%	+0.40%

23.04.	Kiniksa Pharmaceuticals Q1 Verlust weitet sich aus, Umsatz steigt	MT
23.04.	Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	23.04.
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q1 Revenue $79.9M, vs. Street Est of $78.5M	23.04.
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution	23.04.
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	23.04.
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024	16.04.
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	02.04.
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	02.04.
PRACTICE STATEMENT LETTER PROPOSED SCHEME OF ARRANGEMENT IN RESPECT OF: KINIKSA PHARMACEUTICALS, LTD - Form 8-K	29.03.
Kiniksa Pharmaceuticals' Q4 Earnings, Revenue Increase	28.02.
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q4 Revenue $83.4M, vs. Street Est of $72.3M	28.02.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution	28.02.
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28.02.
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024	21.02.
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024	08.01.
Kiniksa Pharmaceuticals Provides Corporate Update	04.01.
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference	02.01.
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M	31.10.23
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023	31.10.23
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31.10.23
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution	31.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kiniksa Pharmaceuticals, Ltd.

Aktien

A2JMVJ

BMG5269C1010

KNSA

Andere Sprachen

Filter